PUCHHEIM, Germany–Sloning BioTechnology GmbH, the worldwide leading supplier of combinatorial gene libraries, received additional investments from all of its institutional shareholders: HBM BioVentures, LBBW Venture, DEWB and KfW to finance the company’s ongoing commercial growth strategy in the field of protein engineering.

“The additional financing is commensurate with the company’s remarkable success as a preferred technology provider, explains Sloning’s Chief Executive Officer, Dr. Heinz Schwer. “Now, that our technology has proven its superior enabling capabilities in the marketplace, the financial resources are required to further support our growth strategy and consolidate Sloning’s leading market position.”

“All of the investors were considerably impressed by the company’s performance and the exciting customer feedback from all of the top pharmaceutical players served by the company. Sloning’s platform technology has clearly become the gold standard in the field of antibody engineering”, says Dr. Harald Poth, chairman of Sloning’s advisory board.

About Sloning

Established in 2001 and based in Puchheim, close-by Munich, Germany, Sloning BioTechnology is a protein engineering company and leading supplier of highly innovative synthetic biology tools. Sloning’s superior combinatorial libraries are unbiased and enable researchers to increase the success rate of their screening for new and optimized therapeutic antibodies, proteins or industrial enzymes. Key to Sloning’s success is the company’s core technology, Slonomics®, a proprietary fully automated genetic-engineering platform that utilises sets of double stranded DNA triplets in the controlled fabrication of highly diverse gene libraries.